Jun 2026 (Q2 FY26) — Aug 5, 2026
AbCellera Q2 FY26 — Strong Liquidity and Pipeline Progress with Key Collaborations
Read the full callAbCellera (ABCL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
AbCellera earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 4.1 | −76.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1550.0 | −1259.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -55.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$11.93 +1.10% · +$0.13
Performance +113.4% 1Y
1Y: $5.59 on 17 Oct 2025 → $11.93. High $14.82 (29 Sept 2026), low $2.78 (5 Feb 2026).
- Previous close
- $11.8
- 52-week range
- $2.78 – $14.82
- One year
- +103.58%
Overview
- Symbol
- ABCL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
AbCellera earnings calls (ABCL)
Financials
What the filings say
Net profit, year on year: −60% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 7 | 5 | 4 | 17 | 9 | 45 | 8 | 4 |
| Operating profit | -94 | -73 | -63 | -50 | -76 | -29 | -58 | -63 |
| Operating margin | −1439.4% | −1441.0% | −1479.6% | −290.2% | −851.8% | −63.7% | −691.8% | −1550.0% |
| Other income | 31 | 26 | 10 | 13 | 8 | 9 | 8 | 4 |
| Profit before tax | -63 | -47 | -53 | -36 | -69 | -19 | -50 | -59 |
| Tax rate | 18.4% | 26.9% | 13.9% | 4.5% | 16.9% | 54.1% | 12.9% | 6.0% |
| Net profit | -51 | -34 | -46 | -35 | -57 | -9 | -43 | -55 |
| EPS ($ per share) | -0.17 | — | -0.15 | -0.12 | -0.19 | — | -0.14 | -0.18 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 710 | 722 | 734 | 753 | 777 | 802 |
| Reserves | — | 114 | 268 | 426 | 280 | 117 | -29 |
| Total liabilities | — | 175 | 293 | 308 | 336 | 304 | 390 |
| Fixed assets | — | 18 | 112 | 217 | — | — | — |
| Total assets | — | 1,006 | 1,319 | 1,541 | 1,488 | 1,361 | 1,357 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | 23 | 245 | 277 | -44 | -109 | -131 |
| Cash from investing | -6 | -120 | -332 | -353 | -221 | 121 | 88 |
| Cash from financing | 0 | 684 | -4 | -2 | 10 | 13 | 14 |
| Net cash flow | -3 | 587 | -93 | -86 | -254 | 23 | -28 |
| Capital expenditure | -4 | -10 | -58 | -71 | -77 | -78 | -43 |
| Free cash flow | -1 | 13 | 186 | 207 | -121 | -187 | -174 |
ABCL revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Research Fees | — | — | 96% | 39% | — | — | 98% | 96% | -41.2% |
| Licensing and Royalty Revenue | — | — | — | — | — | — | 2% | 4% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
12 filings between Nov 26, 2025 and Aug 24, 2026.
Open market
decisions to buy or sellPurchases
$2.68M
9 purchases by 4 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Option exercise — converted options into shares
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Hayden Michael R | $1.05M | — | Aug 24, 2026 |
| Thermopylae Holdings Ltd. | $711.0K | — | Feb 27, 2026 |
| Booth Andrew | $529.6K | — | Aug 14, 2026 |
| Montalbano John S. | $384.2K | — | Aug 18, 2026 |
Latest filings (18)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2026 | Hayden Michael R Director | Purchase | 53,613 | $570.4K |
| Aug 18, 2026 | Montalbano John S. Director | Purchase | 10,000 | $110.3K |
| Aug 14, 2026 | Booth Andrew Chief Financial Officer | Purchase | 37,200 | $383.9K |
| Aug 12, 2026 | Hayden Michael R Director | Purchase | 46,387 | $481.0K |
| Aug 11, 2026 | Hayden Michael R Director | Gift | 50,000 | $0 |
| Jun 3, 2026 | Booth Andrew Chief Financial Officer | Option exercise | 250,000 | $47.5K |
| May 14, 2026 | Montalbano John S. Director | Purchase | 20,000 | $95.4K |
| Feb 27, 2026 | Thermopylae Holdings Ltd. 10% owner | Purchase | 38,000 | $130.7K |
| Feb 27, 2026 | Booth Andrew Chief Financial Officer | Purchase | 42,600 | $145.7K |
| Feb 26, 2026 | Thermopylae Holdings Ltd. 10% owner | Purchase | 177,457 | $580.3K |
| Dec 18, 2025 | Thermopylae Holdings Ltd. 10% owner | Gift | 225,000 | $0 |
| Nov 26, 2025 | Montalbano John S. Director | Purchase | 50,000 | $178.5K |
| Mar 11, 2025 | Thermopylae Holdings Ltd. 10% owner | Purchase | 343,631 | $742.2K |
| Mar 10, 2025 | Montalbano John S. Director | Purchase | 25,000 | $57.5K |
| Mar 6, 2025 | Montalbano John S. Director | Purchase | 60,000 | $140.6K |
| Dec 4, 2024 | Thermopylae Holdings Ltd. 10% owner | Gift | 286,000 | $0 |
| Nov 25, 2024 | Hansen Carl L. G. Chief Executive Officer | Option exercise | 56,125 | $151.5K |
| Sep 20, 2024 | Hansen Carl L. G. Chief Executive Officer | Option exercise | 56,125 | $151.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AbCellera Biologics Inc.
Free account. Everything above stays public.
Write why you follow AbCellera Biologics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading